Guard Medical

Guard Medical reports an $11 million Series B investment for its novel NPseal™, the first all-in-one NPWT surgical dressing 

Miami,  April 6, 2022 –  Privately-held company Guard Medical Inc. today announces the completion of a Series B investment of $11 million to support commercialization and clinical studies of its next generation Negative Pressure Wound Therapy (NPWT) dressing NPseal™ for the treatment of closed surgical incisions. NPseal™ is an easy-to-use and cost-effective NPWT surgical dressing with an integrated pump that establishes and maintains negative pressure with just a few pinches.  

 “The completion of the Series B demonstrates the confidence of the investors to support the next phase of our NPseal™. Securing additional funding will enable new clinical studies, increased commercialization and leveraging the NPseal™ technology into the high exuding and chronic wounds segments,” stated Machiel van der Leest, CEO of Guard Medical. “The now confirmed NPseal™ ease-of-use and cost effectiveness makes, for the first time, prophylactic use of NPWT for all eligible closed surgical incisions possible.” 

NPWT has been shown to reduce Surgical Site Infections (SSI) in a large number of peer reviewed articles but is in limited use due to its high cost and complexity. While being easy-to-use, NPseal™ delivers the same NPWT as the more expensive and complex NPWT competitive devices. 

– end –

 Guard Medical Inc. (, a privately-held company, is developing easy-to-use and cost-effective solutions that enables prophylactic Negative Pressure Wound Therapy (NPWT) wound care of closed surgical incisions. Guard Medical’s simple NPWT technology originated with NewYork-Presbyterian and Weill Cornell Medicine in response to physician’s identification of unmet needs related to Surgical Site Infections (SSI). Current investors include Bpifrance and Matignon Investissement et Gestion.

 Guard Medical’s vision is to develop NPWT solutions for use on a wide range of surgical wound types and sizes with broad applications for infection prevention, scar mitigation and enhanced cosmesis.

For further information please contact:
Dr. Frederick Cornhill
Chief Scientific Officer, Guard Medical

more insights

Negative Pressure Vs. Dermabond

The patient was satisfied with both scars however he preferred the scar which was dressed with the NPseal® dressing.

With the purpose of evaluating the ease of use and the aesthetic result of the NPseal negative pressure wound therapy device, a direct comparison between Dermabond closure and NPseal negative pressure wound therapy was evaluated. Laparoscopic port site incisions were dressed with either Dermabond or the NPseal negative pressure wound therapy device and aesthetic and functional outcomes were evaluated.